Patent ID: 9533000
Date: 2017-01-03
CPC Classifications: A61K,A61P,Y02A

Claim:
1. A method of treating pulmonary infections in a human in need thereof comprising administering to the human a tobramycin aerosol in a treatment cycle of 28 days on the tobramycin aerosol and 28 days off the tobramcycin aerosol; the method comprising administering by inhalation to the human, during the 28 days the human is off the tobramcycin aerosol, an inhalable aerosol comprising from about 1 to about 250 mg of purified aztreonam or a pharmaceutically acceptable salt thereof in a dry powder form dissolved in a saline solution per one dose, said aerosol being suitable for treatment of pulmonary bacterial infections caused by gram-negative bacteria Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans , and multidrug resistant Pseudomonas aeruginosa ; provided that the pharmaceutically acceptable salt of aztreonam is not arginine.